Seqirus, a global leader in influenza prevention and a business of
'It is critical that we do everything we can to protect vulnerable populations like older adults against influenza,' said
Immunosenescence, the age-associated decline of the immune system, may result in a reduced immune response to antigens in the vaccine.2 FLUAD QUADRIVALENT is specifically created for adults 65 years and older using Seqirus' MF59 adjuvant, designed to help strengthen, broaden and lengthen the immune response to influenza vaccination.2, 3, 4, 5 Approximately 80 percent of influenza-related deaths and 50 to 70 percent of influenza-related hospitalizations occur among adults 65 years and older, according to the CDC.6
FLUAD is proven to be safe and effective and has an extensive clinical legacy, with more than 225 million doses distributed and licensure in over 30 countries since it was first approved in 1997.7, 8
More than 20 years of real-world evidence supports the clinical value of FLUAD in reducing influenza-related clinical outcomes in adults 65 years and older across different influenza seasons with different study designs, clinical outcomes, and study limitations.4 Seqirus will offer this enhanced seasonal vaccine option for pharmacy partners, healthcare providers and their patients during the upcoming 2022/23 Northern Hemisphere influenza season in the
'This preferential recommendation sends a clear message that FLUAD QUADRIVALENT is an important treatment option for people 65 years of age and older,' said
Seqirus' differentiated portfolio of seasonal influenza vaccines for the
According to the ACIP, if one of the preferentially recommended influenza vaccines is not available to adults 65 years and older, then any other age-appropriate influenza vaccine should be used.2
About Seasonal Influenza
Influenza is a common, contagious seasonal respiratory disease that may cause severe illness and life-threatening complications in some people.11 Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases, death.11 Because transmission of influenza viruses to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.11 Estimates from the
About Seqirus
Seqirus is part of
About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses,
For more information visit www.seqirus.com and www.csl.com.
Intended Audience
This press release is issued from
Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
Contact:
MEDIA
T: +1 (201) 248-5208
E: Maria.Tortoreto@Seqirus.com
(C) 2022 Electronic News Publishing, source